PureTech Health plc (LON:PRTC – Get Free Report) insider Kiran Mazumdar Shaw purchased 93,944 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was purchased at an average cost of GBX 1 per share, with a total value of £939.44.
PureTech Health Stock Performance
PRTC stock traded down GBX 0.48 during midday trading on Friday, hitting GBX 119.12. The stock had a trading volume of 512,639 shares, compared to its average volume of 1,072,302. The firm has a market capitalization of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33. The stock has a 50-day simple moving average of GBX 127.71 and a 200 day simple moving average of GBX 126.71. PureTech Health plc has a 52 week low of GBX 104.71 and a 52 week high of GBX 146.40.
Wall Street Analyst Weigh In
Separately, Peel Hunt reissued a “buy” rating and set a GBX 508 price objective on shares of PureTech Health in a report on Monday, July 13th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, PureTech Health currently has an average rating of “Buy” and an average target price of GBX 508.
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
See Also
- Five stocks we like better than PureTech Health
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
